NZ596872A - Improved method for synthesizing pirfenidone - Google Patents

Improved method for synthesizing pirfenidone

Info

Publication number
NZ596872A
NZ596872A NZ596872A NZ59687210A NZ596872A NZ 596872 A NZ596872 A NZ 596872A NZ 596872 A NZ596872 A NZ 596872A NZ 59687210 A NZ59687210 A NZ 59687210A NZ 596872 A NZ596872 A NZ 596872A
Authority
NZ
New Zealand
Prior art keywords
pirfenidone
improved method
synthesising
synthesised
butanol
Prior art date
Application number
NZ596872A
Other languages
English (en)
Inventor
Mike Cyr
Ramachadran Radhakrishnan
Sabine Marie-Francoise Brigitte Boutet
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43298478&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ596872(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of NZ596872A publication Critical patent/NZ596872A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NZ596872A 2009-06-03 2010-06-02 Improved method for synthesizing pirfenidone NZ596872A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18358809P 2009-06-03 2009-06-03
PCT/US2010/037090 WO2010141600A2 (en) 2009-06-03 2010-06-02 Improved method for synthesizing pirfenidone

Publications (1)

Publication Number Publication Date
NZ596872A true NZ596872A (en) 2013-12-20

Family

ID=43298478

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ596872A NZ596872A (en) 2009-06-03 2010-06-02 Improved method for synthesizing pirfenidone

Country Status (35)

Country Link
US (6) US20110003863A1 (enExample)
EP (1) EP2440543B1 (enExample)
JP (2) JP5848244B2 (enExample)
KR (1) KR101734858B1 (enExample)
CN (1) CN102482255A (enExample)
AP (1) AP3630A (enExample)
AR (1) AR076974A1 (enExample)
AU (1) AU2010256693B2 (enExample)
BR (1) BRPI1011015B8 (enExample)
CA (1) CA2764043C (enExample)
CL (1) CL2011003069A1 (enExample)
DK (1) DK2440543T3 (enExample)
EA (1) EA021826B1 (enExample)
ES (1) ES2538103T3 (enExample)
GE (1) GEP20156223B (enExample)
HN (1) HN2011003187A (enExample)
HR (1) HRP20150696T1 (enExample)
HU (1) HUE026014T2 (enExample)
IL (1) IL216565A (enExample)
MA (1) MA33489B1 (enExample)
MX (1) MX2011012654A (enExample)
MY (1) MY162443A (enExample)
NI (1) NI201100211A (enExample)
NZ (1) NZ596872A (enExample)
PE (1) PE20120398A1 (enExample)
PL (1) PL2440543T3 (enExample)
PT (1) PT2440543E (enExample)
RS (1) RS54031B1 (enExample)
SG (1) SG176648A1 (enExample)
SI (1) SI2440543T1 (enExample)
TN (1) TN2011000615A1 (enExample)
TW (1) TWI434833B (enExample)
UA (1) UA106759C2 (enExample)
WO (1) WO2010141600A2 (enExample)
ZA (1) ZA201108794B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
EP2296653B1 (en) 2008-06-03 2016-01-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
HUE058753T2 (hu) 2011-01-31 2022-09-28 Avalyn Pharma Inc Aeroszol formájú pirfenidon- és piridon-analóg vegyületek és alkalmazásaik
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
JP7066321B2 (ja) 2014-01-10 2022-05-13 アヴァリン ファーマ インク. エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
RU2692485C2 (ru) 2014-04-02 2019-06-25 Интермьюн, Инк. Противофиброзные пиридиноны
EP3180026A4 (en) * 2014-08-15 2018-04-11 Pixarbio Corporation Compositions for inhibiting inflammation in a subject with a spinal cord injury and methods of using the same
WO2016122420A1 (en) 2015-01-26 2016-08-04 Ulkar Kimya Sanayii Ve Ticaret A. S. An improved method for the synthesis and purification of pirfenidone
ITUB20154832A1 (it) 2015-10-29 2017-04-29 Procos Spa Processo per la sintesi di pirfenidone
CN105315198A (zh) * 2015-11-02 2016-02-10 重庆康乐制药有限公司 一种吡非尼酮的晶型及其制备方法
CN105330598B (zh) * 2015-12-02 2017-11-14 新发药业有限公司 一种吡非尼酮的制备方法
US11066368B2 (en) 2016-01-14 2021-07-20 Laurus Labs Limited Process for the preparation and particle size reduction of pirfenidone
WO2017122139A1 (en) * 2016-01-14 2017-07-20 Laurus Labs Limited An improved process for the preparation of pirfenidone
WO2017130166A1 (en) * 2016-01-31 2017-08-03 Granules India Limited An improved process for the preparation of highly pure anti-fibrotic drug
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
US20180009753A1 (en) * 2016-07-08 2018-01-11 Dipharma Francis S.R.L. Method for preparing an antifibrotic agent
IT201600108927A1 (it) * 2016-10-27 2018-04-27 Dipharma Francis Srl Metodo per sintetizzare un farmaco antifibrotico
IT201600071672A1 (it) * 2016-07-08 2018-01-08 Dipharma Francis Srl Metodo per sintetizzare un farmaco immunosoppressore
WO2018083709A1 (en) * 2016-11-07 2018-05-11 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of pure 5-methyl-1-phenyl-2-1 (h)-pyridone
WO2018178996A1 (en) * 2017-03-28 2018-10-04 Natco Pharma Limited Improved process for the preparation of pirfenidone
CA3108048A1 (en) 2017-07-31 2019-02-07 Washington University Pirfenidone derivatives for modulation of b lymphocyte activity and organ protection
EP3494965B1 (en) 2017-12-11 2021-06-02 Laurus Labs Limited An improved process for the preparation of pirfenidone
MX368750B (es) 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
CN112409246B (zh) * 2019-08-21 2023-04-07 北京凯因科技股份有限公司 一种吡非尼酮的晶型及其制备方法
JP7490813B2 (ja) * 2020-04-22 2024-05-27 ユンジン ファーム.カンパニー、リミテッド 安全性と安定性が改善されたピルフェニドンを含む腸溶性製剤およびその製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839346A (en) * 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
CA2099868C (en) * 1991-01-31 2002-04-02 Thomas Richard Belliotti Substituted 4,6-di-tertiary-butyl-5-hydroxy-pyrimidines
JPWO2002085858A1 (ja) * 2001-04-20 2004-08-12 旭硝子株式会社 精製されたピペリジン誘導体の製造方法
KR100898888B1 (ko) * 2001-08-06 2009-05-21 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2(1h)피리디논의 제조 방법
CN1218942C (zh) 2002-06-11 2005-09-14 中南大学湘雅医学院 抗纤维化吡啶酮化合物及其生产工艺方法
CN100396669C (zh) * 2006-03-15 2008-06-25 浙江省医学科学院 一种抗纤维化药物吡非尼酮的制备方法
MX2007006349A (es) 2007-05-29 2009-02-18 Cell Therapy And Technology S Nuevo proceso de sintesis para la obtencion de 5-metil-1-fenil-2-(ih)-piridona, composicion y uso de la misma.
AU2008265595B2 (en) 2007-06-20 2014-12-04 PureTech LYT 100 Inc. Substituted N-Aryl pyridinones as fibrotic inhibitors
US20090131485A1 (en) * 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone

Also Published As

Publication number Publication date
EA021826B1 (ru) 2015-09-30
RS54031B1 (sr) 2015-10-30
BRPI1011015B8 (pt) 2021-05-25
ZA201108794B (en) 2013-03-27
UA106759C2 (uk) 2014-10-10
PT2440543E (pt) 2015-07-03
US20140221660A1 (en) 2014-08-07
GEP20156223B (en) 2015-01-26
IL216565A0 (en) 2012-03-01
KR101734858B1 (ko) 2017-05-12
MX2011012654A (es) 2012-01-12
NI201100211A (es) 2012-08-01
CA2764043C (en) 2018-01-16
US20150065720A1 (en) 2015-03-05
CA2764043A1 (en) 2010-12-09
JP2012528877A (ja) 2012-11-15
CN102482255A (zh) 2012-05-30
AU2010256693A1 (en) 2012-01-12
AR076974A1 (es) 2011-07-20
EA201101695A1 (ru) 2012-05-30
US20130345430A1 (en) 2013-12-26
JP2016026196A (ja) 2016-02-12
EP2440543A4 (en) 2012-11-21
PL2440543T3 (pl) 2015-09-30
ES2538103T3 (es) 2015-06-17
SG176648A1 (en) 2012-01-30
AP3630A (en) 2016-03-08
HRP20150696T1 (hr) 2015-08-28
CL2011003069A1 (es) 2012-05-25
US20150368200A1 (en) 2015-12-24
HUE026014T2 (en) 2016-05-30
MY162443A (en) 2017-06-15
BRPI1011015A2 (pt) 2018-02-14
MA33489B1 (fr) 2012-08-01
US8519140B2 (en) 2013-08-27
HN2011003187A (es) 2015-02-02
WO2010141600A2 (en) 2010-12-09
TWI434833B (zh) 2014-04-21
KR20120016277A (ko) 2012-02-23
TN2011000615A1 (en) 2013-05-24
EP2440543A2 (en) 2012-04-18
US20110003863A1 (en) 2011-01-06
AU2010256693B2 (en) 2015-09-17
SI2440543T1 (sl) 2015-06-30
BRPI1011015B1 (pt) 2020-11-10
DK2440543T3 (en) 2015-05-18
TW201043602A (en) 2010-12-16
IL216565A (en) 2015-06-30
PE20120398A1 (es) 2012-05-13
US20120016133A1 (en) 2012-01-19
WO2010141600A3 (en) 2011-04-21
AP2012006052A0 (en) 2012-02-29
EP2440543B1 (en) 2015-04-15
JP5848244B2 (ja) 2016-01-27

Similar Documents

Publication Publication Date Title
TN2011000615A1 (en) Improved method for synthesizing pirfenidone
NZ705827A (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
JO3178B1 (ar) النموذج السادس البلوري الجديد من مركب الاغوميلاتين وطريقة تحضيره وتحضير المركبات الصيدلانية المحتوية عليه
WO2009006590A3 (en) Docetaxel process and polymorphs
MX2014005245A (es) Metodo de preparacion de acetato de ulipristal y su intermediario.
GEP20094577B (en) New crystalline form iv of agomelatine, a process for its preparation and pharmaceutical compositions containing it
PH12012501918A1 (en) Process for preparation of dopo-derived compounds and compositions thereof
MY198086A (en) Method for producing substituted 5-fluoro-1h-pyrazolopyridines
GB0916848D0 (en) Crystalline compound
GEP20094576B (en) New cyrstalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing it
TN2012000435A1 (en) Agomelatine hydrochloride hydrate and preparation thereof
IN2012DN03176A (enExample)
IL265947A (en) Preparation of stansoporfin with a high degree of purification on a large scale
MX2010009860A (es) Sintesis total de salinosporamida a y sus analogos.
WO2010116140A8 (en) New process for preparing hydroxylamines and medicaments
DE502005010342D1 (en) Substituierte cyclohexylessigsäure-derivate
RU2011148101A (ru) Новые кристаллы сольватов
WO2010122575A3 (en) Process for the preparation of pure paliperidone
RU2015107017A (ru) Получение иоформинола-рентгеноконтрастного агента
UA99904C2 (ru) Производство станнсопорфина высокой чистоты
MX2009001508A (es) Un proceso novedoso para preparar ester de acido 3-amino-5-fluoro-4-dialcoxipentanoico.
SG168483A1 (en) New piperidine compounds, a process for their preparation and pharmaceutical compositions containing them
NZ718051A (en) Intermediates useful in the synthesis of deoxycholic acid
UA88108C2 (ru) Способ получения карбида кремния

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 02 JUN 2017 BY CPA GLOBAL

Effective date: 20140410

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JUN 2018 BY CPA GLOBAL

Effective date: 20170505

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JUN 2019 BY CPA GLOBAL

Effective date: 20180426

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JUN 2020 BY CPA GLOBAL

Effective date: 20190425

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JUN 2021 BY CPA GLOBAL

Effective date: 20200507

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JUN 2022 BY CPA GLOBAL

Effective date: 20210415

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JUN 2023 BY CPA GLOBAL

Effective date: 20220512

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JUN 2024 BY CPA GLOBAL

Effective date: 20230504

LAPS Patent lapsed